Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Core Viewpoint - Xenetic Biosciences, Inc. has announced the pricing of an underwritten offering of common stock aimed at raising approximately $4.5 million to support its biopharmaceutical initiatives in immuno-oncology [1] Group 1: Offering Details - The company is offering 735,000 shares of common stock at a public price of $6.12 per share [1] - The gross proceeds from this offering are expected to be around $4.5 million before deducting underwriting discounts, commissions, and other estimated offering expenses [1] - All shares being offered are from Xenetic itself, indicating a primary offering rather than a secondary one [1]